SMAGP a Novel Biomarker of Cervical Cancer Development and Progression [Erratum]

Jia Y, Li H, Liu G, Song F. *OncoTargets Ther.* 2018;11:6925–6935.

during the publication process. The correct Figure 4 is as follows:

On page 6933, Figure 4B artwork is incorrect. Figure 4B artwork was mistakenly interchanged by the Editorial staff

Figure 4 SMAGP down-regulation inhibited the migration and invasion ability of cervical cancer cells.

Notes: (A, B) SMAGP was knocked down with siRNA (siNC and si581) and lentivirus (shNC, shSMAGP). Knockdown of SMAGP inhibited CaSki cell migration and invasion. (C) Knockdown of SMAGP inhibits CaSki metastasis in nude mice. CaSki cells stably expressing shSMAGP were injected into nude mice twice per week. At 28 days after injection, the tumor mass and related tissues were removed. In the NC group, many tumors were found around the intestine; however, tumors only developed at the injection site in the experimental group. Ascites extracted from the NC group exhibited green fluorescence. ** $P < 0.01$, *** $P < 0.001$. Magnification 100 $\times$.

Abbreviation: NC, normal cells.

OncoTargets and Therapy**Dovepress****Publish your work in this journal**

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>